The city of Durham, North Carolina, currently has 7 active clinical trials seeking participants for Epilepsy research studies.
A Phase 1/2 Study of NRTX-1001 Neuronal Cell Therapy in Drug-Resistant Bilateral Mesial Temporal Lobe Epilepsy (MTLE)
NCT06422923
Recruiting
This is a multicenter, single arm, open label clinical trial that is designed to test the safety and preliminary efficacy of single administration inhibitory nerve cells called interneurons (NRTX-1001), into both temporal lobes of subjects with drug-resistant bilateral mesial temporal lobe epilepsy.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
08/01/2025
Locations: Duke University Hospital, Durham, North Carolina
Conditions: Epilepsy, Temporal Lobe
Register for Updates
Safety and Efficacy Study of Cenobamate in Pediatric Subjects 2-17 Years of Age With Partial-onset (Focal) Seizures
NCT05067634
Recruiting
Primary objective: To evaluate the safety and tolerability of cenobamate in pediatric subjects 2-17 years of age with partial-onset (focal) seizures
Gender:
ALL
Ages:
Between 2 years and 18 years
Trial Updated:
07/23/2025
Locations: Duke University Hospital, Durham, North Carolina
Conditions: Partial Epilepsy
Register for Updates
A Study to Test the Safety and Tolerability of Brivaracetam in Children and Adolescents With Seizures
NCT04715646
Recruiting
The purpose of the study is to evaluate the long-term safety and tolerability of brivaracetam.
Gender:
ALL
Ages:
1 month and above
Trial Updated:
06/26/2025
Locations: Ep0156 237, Durham, North Carolina
Conditions: Epilepsy
Register for Updates
FIH Study of NRTX-1001 Neural Cell Therapy in Drug-Resistant Unilateral Mesial Temporal Lobe Epilepsy
NCT05135091
Recruiting
This clinical trial is designed to test whether a single image-guided intracerebral administration of inhibitory nerve cells, called interneurons (NRTX-1001), into subjects with drug-resistant unilateral mesial temporal lobe epilepsy (MTLE), with or without mesial temporal sclerosis (MTS), is safe (frequency of adverse events) and effective (seizure frequency). NRTX-1001 comprises human interneurons that secrete a neurotransmitter, gamma-aminobutyric acid (GABA).
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
04/03/2025
Locations: Duke University Hospital, Durham, North Carolina
Conditions: Mesial Temporal Lobe Epilepsy
Register for Updates
Neonatal Seizure Registry, GEnetics of Post-Neonatal Epilepsy
NCT05361070
Recruiting
The NSR-GENE study is a longitudinal cohort study of approximately 300 parent-child trios from the Neonatal Seizure Registry and participating site outpatient clinics that aims to evaluate whether and how genes alter the risk of post-neonatal epilepsy among children with acute provoked neonatal seizures. The researchers aim to develop prediction rules to stratify neonates into low, medium, and high risk for post-neonatal epilepsy based on clinical, electroencephalogram (EEG), magnetic resonance... Read More
Gender:
ALL
Ages:
All
Trial Updated:
04/02/2025
Locations: Duke University, Durham, North Carolina
Conditions: Neonatal Seizure, Hypoxic-Ischemic Encephalopathy, Stroke, Intracranial Hemorrhage, Epilepsy, Gene Abnormality
Register for Updates
Dose-Escalation Study of Cenobamate (YKP3089) in Pediatric Subjects with Partial-Onset Seizures
NCT04903314
Recruiting
The primary objective of this study is to assess the pharmacokinetics of cenobamate (YKP3089) in pediatric subjects with partial-onset (focal) seizures following single and multiple-dosing.
Gender:
ALL
Ages:
Between 2 years and 18 years
Trial Updated:
03/03/2025
Locations: Duke University, Durham, North Carolina
Conditions: Partial Epilepsy
Register for Updates
Lemborexant Treatment of Insomnia Linked to Epilepsy
NCT06262594
Recruiting
The goal of this clinical trial is to assess whether Lemborexant can improve sleep in patients with epilepsy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/10/2025
Locations: Duke University, Durham, North Carolina
Conditions: Epilepsy, Sleep
Register for Updates